Table 2.
Characteristics of PBC patients and controls
| Controls (n = 48) | PBC (all) (n = 48) | p-valuea | PBC (early) (n = 24) | PBC (late) (n = 24) | p-valueb | |
|---|---|---|---|---|---|---|
| Sex, % male | 12.5 | 12.5 | > 0.9999 | 8.3 | 16.7 | 0.6662 |
| Race, % Caucasian | 98 | 91.7 | 0.3616 | 95.8 | 87.5 | 0.6085 |
| Age at sample collection (yrs), median (IQR) | 56.3 (48.2–61.0) | 56.3 (41.3–56.5) | 0.9927 | 57.8 (53.3–62.2) | 51.7 (46.5–61.0) | 0.1071 |
| ALP (xULN), median (IQR) | 0.60 (0.48–0.73) | 1.17 (0.83–4.02) | < 0.0001 | 0.83 (0.71–0.94) | 3.98 (3.17–5.33) | < 0.0001 |
| AMA, (% positive) | 0 | 81.3 | < 0.0001 | 79.2 | 83.3 | > 0.9999 |
| Age at Dx (yrs), median (IQR) | na | 49.4 (41.3–56.5) | – | 52.1 (46.3–57.4) | 42.9 (39.9–51.9) | 0.0185 |
| Disease duration (yrs), median (IQR) | na | 5.0 (2.0–9.0) | – | 4.5 (2.0–9.0) | 5.5 (2.0–10.8) | 0.6116 |
| Clin. FU (yrs), median (IQR) | na | 6.0 (4.0–10.0) | – | 8.5 (5.3–10.0) | 5.0 (2.0–8.8) | 0.0133 |
| UDCA treatment, (%) | na | 97.9 | – | 100 | 95.8 | > 0.9999 |
ap-value for control versus PBC (all) comparison
bp-value for PBC (early) versus PBC (late) comparison; ALP (xULN): alkaline phosphatase expressed as times the upper limit of normal, AMA: anti-mitochondrial antibodies, Clinical FU: clinical follow-up after sample collection, UDCA: ursodeoxycholic acid